LIQREV

Growth

sildenafil citrate

NDAORALSUSPENSION
Approved
Apr 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
6

Clinical Trials (5)

NCT04391868Phase 1Withdrawn

A Bioequivalence Study of Sildenafil Citrate Orally-Disintegrating Film Dosage Form

Started Jan 2021
0
Healthy
NCT01334554Phase 1/2Completed

Study of Sildenafil Citrate on Insulin Resistance in African American

Started Apr 2011
46 enrolled
Metabolic SyndromeObesity
NCT00904748Phase 1Completed

A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate

Started Jan 2010
47 enrolled
Erectile Dysfunction
NCT00141310Phase 2Terminated

Sildenafil Citrate for the Treatment of Established Pre-Eclampsia

Started Sep 2004
76 enrolled
Pre-eclampsia
NCT00159874Phase 3Completed

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

Started Jan 2004
234 enrolled
Pulmonary Arterial Hypertension

Loss of Exclusivity

LOE Date
Dec 24, 2038
155 months away
Patent Expiry
Dec 24, 2038

Patent Records (5)

Patent #ExpiryTypeUse Code
11337979
Dec 24, 2038
Product
U-3582
11464778
Dec 24, 2038
Product
U-3582
11759468
Dec 24, 2038
Product
U-3582
12005062
Dec 24, 2038
Product
U-3582
12186321
Dec 24, 2038
Product
U-3582
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers